Search results for "type 1"

showing 10 items of 540 documents

Leukocyte adhesion deficiency type I - a focus on oral disease in a young child

2010

This paper presents a case of the moderate form of Leukocyte adhesion deficiency type 1 (LAD-1) in a 4 year-old boy. LAD-1 is a rare, inherited immunodeficiency that affects 1 in 1 million people yearly. Affected patients are susceptible to recurrent bacterial and fungal infections, impaired pus formation and delayed wound healing. In the oral clinical finding, more important is a generalized prepuberal periodontitis that can affect the primary and permanent dentitions. For this reason cooperation between dentists and pediatricians is essential in these patients. Evaluating immune system in these patients included peripheral blood leukocyte counts, measurement of serum immunoglobulin levels…

MalePeriodontitisYoung childbusiness.industryLeukocyte-Adhesion Deficiency SyndromePrenatal diagnosismedicine.disease:CIENCIAS MÉDICAS [UNESCO]Leukocyte Adhesion Deficiency Type 1Immune systemOtorhinolaryngologyChild PreschoolUNESCO::CIENCIAS MÉDICASImmunologymedicineHumansSurgeryOral diseasePeriodontitisbusinessGeneral DentistryImmunodeficiencyLeukocyte adhesion deficiency
researchProduct

Two distinct phenotypes, hemiplegic migraine and episodic Ataxia type 2, caused by a novel common CACNA1A variant

2020

Abstract Background To investigate the genetic and environmental factors responsible for phenotype variability in a family carrying a novel CACNA1A missense mutation. Mutations in the CACNA1A gene were identified as responsible for at least three autosomal dominant disorders: FHM1 (Familial Hemiplegic Migraine), EA2 (Episodic Ataxia type 2), and SCA6 (Spinocerebellar Ataxia type 6). Overlapping clinical features within individuals of some families sharing the same CACNA1A mutation are not infrequent. Conversely, reports with distinct phenotypes within the same family associated with a common CACNA1A mutation are very rare. Case presentation A clinical, molecular, neuroradiological, neuropsy…

MaleProbandmedicine.medical_specialtyNeurologyMigraine with AuraFamilial hemiplegic migraine type 1Mutation MissenseneuropsychologyCase Reportmedicine.disease_causeNystagmus Pathologiclcsh:RC346-42903 medical and health sciences0302 clinical medicinemedicineHumansSpinocerebellar ataxia type 6Missense mutationFamilyChildFamilial hemiplegic migrainelcsh:Neurology. Diseases of the nervous system030304 developmental biologyEpisodic ataxiaGenetics0303 health sciencesMutationbusiness.industryCACNA1A geneEpisodic ataxia type2Cognitive affective syndromeGeneral Medicinemedicine.diseasePhenotypePhenotypeAtaxiaCalcium ChannelsNeurology (clinical)businessCognitive affective syndrome neuropsychology.030217 neurology & neurosurgeryBMC Neurology
researchProduct

Proteomic signature of the Dravet syndrome in the genetic Scn1a-A1783V mouse model.

2021

Abstract Background Dravet syndrome is a rare, severe pediatric epileptic encephalopathy associated with intellectual and motor disabilities. Proteomic profiling in a mouse model of Dravet syndrome can provide information about the molecular consequences of the genetic deficiency and about pathophysiological mechanisms developing during the disease course. Methods A knock-in mouse model of Dravet syndrome with Scn1a haploinsufficiency was used for whole proteome, seizure, and behavioral analysis. Hippocampal tissue was dissected from two- (prior to epilepsy manifestation) and four- (following epilepsy manifestation) week-old male mice and analyzed using LC-MS/MS with label-free quantificati…

MaleProteomics0301 basic medicineProteomeHippocampusEpilepsies MyoclonicHaploinsufficiencyScn1aHippocampusSynaptic TransmissionElevated Plus Maze TestEpilepsyMice0302 clinical medicineTandem Mass Spectrometry11-beta-Hydroxysteroid Dehydrogenase Type 1Genetic epilepsyCarbon-Nitrogen LigasesGene Knock-In TechniquesGliosisNeuronal PlasticityBehavior AnimalEpileptic encephalopathyImmunohistochemistryAstrogliosisNeurologyProteomeDisease ProgressionFemaleHaploinsufficiencySignal TransductionRC321-571Dopamine and cAMP-Regulated Phosphoprotein 32Neovascularization PhysiologicNeurosciences. Biological psychiatry. NeuropsychiatryBiologyNitric Oxide03 medical and health sciencesDravet syndromemedicineAnimalsHyperthermiaSocial Behaviorras-GRF1Proteomic Profilingmedicine.diseaseVascular Endothelial Growth Factor Receptor-2NAV1.1 Voltage-Gated Sodium ChannelDisease Models Animal030104 developmental biologyRotarod Performance TestSynaptic plasticityEpileptic Encephalopathy ; Genetic Epilepsy ; Mice ; Proteome ; Scn1aCalcium-Calmodulin-Dependent Protein Kinase Type 2Open Field TestNeuroscience030217 neurology & neurosurgeryChromatography Liquid
researchProduct

Transforming growth factor β1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive s…

2005

Objective To verify the benefit of renin–angiotensin system blockade in hypertension, the effects of 24 weeks’ losartan and ramipril treatment, both alone and in combination, on urinary albumin excretion (UAE) and circulating transforming growth factor b1 (TGFb1) have been evaluated in hypertensive subjects with minor renal abnormalities. Design and methods Fifty-one patients with stage 1 and 2 essential hypertension and with UAE >—20 mg/24 h but with maintained renal function have been included. After a 4-week run-in with placebo administration, a randomized double-blind, three-arm double-dummy trial was used. All the hypertensives (HT) were allocated randomly to three treatment arms (1…

MaleRamiprilmedicine.medical_specialtyAngiotensin receptorHypertension RenalPhysiologyAngiotensin-Converting Enzyme InhibitorsPharmacologyKidneySeverity of Illness IndexLosartanAce-inhibitors Angiotensin II receptor blockers hypertensive renal disease transforming growth factor β1.Transforming Growth Factor beta1transforming growth factor b1RamiprilTransforming Growth Factor betaInternal medicineInternal MedicinemedicineHumansRenal Insufficiencybusiness.industryMiddle AgedAngiotensin IIBlockadeangiotensin II receptor blockerEndocrinologyLosartanhypertensive renal diseaseRenal physiologyACE inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessangiotensin-converting enzyme-inhibitorAngiotensin II Type 1 Receptor BlockersBiomarkersTransforming growth factormedicine.drug
researchProduct

Cuestionario de adaptación a la diabetes-mellitus tipo I en pediatría: relación con la psicopatología

2018

ABSTRACT Objective: to study the psychometric properties of an adaptive disease response questionnaire for use with Spanish children with type 1 diabetes; to analyse this response in this sample and to observe the relationship between adaptive response and levels of anxiety-depression. Method: a total of 100 patients with type 1 diabetes aged between nine and 16 years (M=12.28, SD=1.78) participated in the study, of which 59% were children. Data was collected in public hospitals via interviews using the Adaptive Disease Response Questionnaire and Anxiety and Depression Scale. The data was analysed using Pearson correlations, multiple hierarchical linear regressions, Student’s t Test for ind…

MaleResposta AdaptativaAdolescentPsychometrics030209 endocrinology & metabolismPatient Health QuestionnaireAnxietyDiabetes Mellitus Tipo 1Severity of Illness IndexPediatrics03 medical and health sciencesAnsiedad0302 clinical medicineDiabetes Mellitus Type I030225 pediatricsDepresiónHumansAnsiedadeRespuesta AdaptativaChildlcsh:RT1-120Pediatrialcsh:NursingDepressionPediatríaReproducibility of ResultsOriginal ArticlesDiabetes Mellitus Type 1Adaptive ResponsePsicometríaFemaleDepressãoPsicometriaPsychometric
researchProduct

Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

2018

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the…

MaleRiskmedicine.medical_specialtyCaseinBreastfeeding030209 endocrinology & metabolism610 Medicine & health2700 General MedicineEndocrinology and DiabetesDisease-Free Survivallaw.inventionFollow-Up StudieNutrition Policy03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodSDG 3 - Good Health and Well-beinglawInternal medicineDiabetes mellitusmedicineHumansCumulative incidence030212 general & internal medicineChildInfant Nutritional Physiological PhenomenaOriginal Investigation2. Zero hungerType 1 diabetesbusiness.industryHazard ratioAbsolute risk reductionInfant NewbornCaseinsGeneral Medicineta3121medicine.diseaseInfant Formula3. Good healthDiabetes Mellitus Type 1Infant formula10036 Medical ClinicEndokrinologi och diabetesFemalebusinessHumanFollow-Up Studies
researchProduct

Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygena…

2002

Angiotensin II (Ang II) may be a key molecule in the development of atherosclerosis. Because the incidence of coronary atherosclerosis in premenopausal women is lower than that observed in men or postmenopausal women, we have investigated the effect of estrogens on Ang II–induced leukocyte recruitment in vivo using intravital microscopy in the rat mesenteric microcirculation. Superfusion for 60 minutes with Ang II induced a significant increase in leukocyte rolling flux, adhesion, and emigration. Administration of 17-β-estradiol (17-β-E) after 30 minutes of Ang II superfusion produced a reduction of these leukocyte responses by 55.1%, 72.7%, and 70.9%, respectively, an additional 30 minutes…

MaleSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyEndotheliumPhysiologyLeukocyte RollingProstacyclinCell CommunicationBiologyIn Vitro TechniquesLosartanReceptor Angiotensin Type 1Lymphatic SystemRats Sprague-DawleyAngiotensin Receptor AntagonistsCell MovementInternal medicinemedicineCell AdhesionLeukocytesAnimalsHumansSplanchnic CirculationEnzyme InhibitorsCells CulturedVenuleEstradiolAngiotensin IIEstrogen AntagonistsAntibodies MonoclonalEstrogensAngiotensin IIEpoprostenolRatsEndothelial stem cellNitric oxide synthasemedicine.anatomical_structureEndocrinologyProstaglandin-Endoperoxide Synthasesbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsIntravital microscopymedicine.drugCirculation research
researchProduct

Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabet…

2016

Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg …

MaleSettore MED/09 - Medicina InternaAntihypertensive agentsPhysiologyMissed DoseTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyPharmacologyEssential hypertensionlaw.invention0302 clinical medicineDiabetes mellitusRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerDrug CombinationPerindoprilMedicine030212 general & internal medicineAntihypertensive agentTetrazoleImidazolesSettore MED/37 - NeuroradiologiaMiddle AgedCalcium Channel BlockersDrug CombinationsTreatment OutcomeHypertensionFemaleEssential HypertensionOlmesartanCalcium Channel BlockerCardiology and Cardiovascular MedicineType 2circulatory and respiratory physiologymedicine.drugHumanAdultmedicine.medical_specialtyAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineDiabetes mellitumissed dose; hypertension; therapeutic efficacyCombination therapyUrologytherapeutic efficacyNOMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal MedicineHumansOlmesartanAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilImidazolemissed doseAgedbusiness.industryAngiotensin-Converting Enzyme Inhibitormedicine.diseaseAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineBlood pressureDiabetes Mellitus Type 2PerindoprilAmlodipinebusinessAngiotensin II Type 1 Receptor Blockers
researchProduct

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

2013

Purpose: This post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese (BMI ≥30 kg/m 2 ) and non-obese (BMI <30 kg/m 2 ) diabetic subjects. Methods: This was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids was estimated. Results: In obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/ simvastatin vs doubling the baseline statin dose or switchi…

MaleSimvastatinApolipoprotein BEndocrinology Diabetes and MetabolismAtorvastatinClinical Biochemistrychemistry.chemical_compoundEndocrinologyAtorvastatinRosuvastatin CalciumSulfonamidesNutrition and DieteticsbiologyAnticholesteremic AgentsDiabetesMiddle AgedRosuvastatin CalciumTreatment OutcomeFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyRosuvastatinYoung AdultEzetimibeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansPyrrolesRosuvastatinObesitycardiovascular diseasesAgedApolipoproteins BBiochemistry medicalCholesterolbusiness.industryResearchBiochemistry (medical)Statinnutritional and metabolic diseasesCholesterol LDLEzetimibemedicine.diseasePeptide FragmentsFluorobenzenesDiabetes Mellitus Type 1PyrimidinesEndocrinologyDiabetes Mellitus Type 2chemistryHeptanoic AcidsSimvastatinbiology.proteinAzetidinesEzetimibe/simvastatinbusinessLipids in Health and Disease
researchProduct

Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective,…

2007

OBJECTIVE - It is still controversial whether sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) are equally effective in patients with diabetes. In these patients, multiple individual variables may be responsible for neointimal hyperplasia, thus making difficult the comparison of the two drug-eluting stents (DES). RESEARCH DESIGN AND METHODS - We designed a prospective, randomized study to compare the efficacy in prevention of restenosis of SES and PES, both implanted in the same diabetic patient with multiple de novo coronary artery lesions undergoing elective percutaneous coronary intervention. We enrolled 60 patients with diabetes with at least two significant de novo angi…

MaleSirolimusPaclitaxel-Eluting StentPaclitaxelAntineoplastic AgentsCoronary DiseaseDrug-Eluting StentsMiddle AgedCoronary AngiographySirolimus; Paclitaxel-Eluting Stent; Coronary Artery LesionsAnti-Bacterial AgentsCoronary RestenosisDiabetic Patient.Diabetes Mellitus Type 1Diabetes Mellitus Type 2Coronary Artery LesionsHumansFemalerestenosiProspective StudiesDiabetic AngiopathiesAgedDiabetes care
researchProduct